Anti-TNF

The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...

Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.

Anti‑TNF drugs are a mainstay of IBD treatment. Understanding that they act through several immune mechanisms (not only neutralizing soluble TNF‑α) helps explain differences in effectiveness and informs conversations...

The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...

The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...

Crohn's-like disease of the pouch is a meaningful complication after IPAA that can impair quality of life and risk pouch failure; knowing which drug classes show promise for specific pouch phenotypes can guide...

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

Some rare autoinflammatory disorders can look like IBD but need different diagnostic thinking. Recognizing systemic signs and checking serum zinc may lead to a correct diagnosis and targeted care.

Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...

This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...

Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...

People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...

This study compares two commonly used anti‑TNF biologics in children with Crohn’s disease using real‑world prospective data, so its findings are directly relevant to treatment choice, expectations for 1‑year remission,...

The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...

High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...

Faster remission can reduce symptoms, school disruption, and steroid exposure for children with IBD. If earlier infliximab level checks reliably speed remission, clinicians could adjust dosing sooner to improve outcomes.

Injection site pain and local reactions can affect comfort and willingness to continue injectable biologic therapy.

The study highlights factors linked to needing another operation after ileocecal resection for Crohn’s disease and suggests postoperative biologic therapy may lower long-term reoperation risk. That directly affects...

This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...

This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...

Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...

People with IBD sometimes are excluded from or uncertain about immune checkpoint inhibitor cancer trials because of concerns about triggering autoimmune flares. This trial explicitly studies safety and disease impact in...

A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...

This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...

Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...

People with IBD and those on commonly used biologics may have different early T cell responses and faster waning after SARS-CoV-2 vaccination, which could affect timing or interpretation of immune monitoring and booster...

Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.

Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...

This study suggests a specific gut microbe might reduce gut inflammation in a mouse colitis model and may boost the benefit of infliximab, which could point toward microbiota‑based adjuncts to current IBD therapies.

Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...

Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...

A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...

People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...

This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.

Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...

Label updates for INFLECTRA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and safety warnings for a commonly used anti-TNF biologic/biosimilar. The label...

Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...

This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...

People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.

The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...

Patients and caregivers considering or subject to insurance-driven switches from adalimumab originator to a biosimilar may want to know whether clinical status and medication continuation remain similar after switching.

This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...

This study compares many targeted IBD drugs indirectly to help clarify how subcutaneous vedolizumab stacks up against other biologics and newer oral therapies — information that could inform treatment discussions for...

VEOIBD often has a strong genetic component and different clinical needs than adult IBD; this study shows genetic findings and treatment challenges in a Middle East pediatric center, which may affect diagnosis and access...

Infliximab dosing can be hard to personalize. This study shows that selecting pharmacokinetic models based on IBD type and severity can improve how well drug levels are predicted, which could help tailor dosing for...

This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.

Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.

Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.